SABCS 2021
Elacestrant showed a statistically significant and clinically meaningful progression-free survival improvement compared with standard of care.
SABCS 2022
Camizestrant improved progression-free survival vs fulvestrant in postmenopausal patients with ER+, HER2- advanced breast cancer.
SABCS 2021
Monitoring bESR1mut enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.
News
Psoriasis may be another risk factor for infectious complications in patients receiving dialysis, according to investigators.
SABCS 2022
The duration of prior treatment with a CDK4/6 inhibitor appears to impact progression-free survival with elacestrant in ER+/HER2- metastatic breast cancer.
News
Although more research is needed, data suggest that the cardioprotective effect of direct oral anticoagulants may extend to patients with advanced CKD.
News
In patients with IgA nephropathy, dapagliflozin significantly reduced the risk of CKD progression when added to ACEi/ARB therapy.
News
Investigators report results from a systematic review and meta-analysis of data from 23 randomized controlled trials involving 15,144 patients with anemia of CKD.
News
Study findings do not support initiation of uric acid-lowering therapy to prevent CKD.
News
The systematic review and meta-analysis included a broad range of patients with and without chronic kidney disease.
